Literature DB >> 14739300

Src kinase activity is essential for osteoclast function.

Tsuyoshi Miyazaki1, Archana Sanjay, Lynn Neff, Sakae Tanaka, William C Horne, Roland Baron.   

Abstract

Deletion of the c-src gene impairs osteoclast bone resorbing activity, causing osteopetrosis. Although it has been concluded that restoring only the Src adaptor function at least partly rescues the cell attachment and skeletal phenotypes, the contribution of Src kinase activity remains controversial. Src forms a complex with Pyk2 and Cbl after adhesion-induced stimulation of alpha(V)beta(3) integrin. To demonstrate the importance of the Pyk2-Src association in osteoclasts and to distinguish the contributions of the Src adaptor and kinase activities in cytoskeletal organization and osteoclast function, we expressed mutants of Src and Pyk2 in osteoclasts using adenovirus vectors. Eliminating the Src-binding site on Pyk2 (Pyk2(Y402F)) markedly inhibited bone resorption by osteoclast-like cells, whereas kinase-dead Pyk2 had little effect. Kinase-dead Src, unlike kinase-dead Pyk2, markedly inhibited the bone-resorbing activity of wild type osteoclasts and failed to significantly restore bone-resorbing activity to Src(-/-) osteoclast-like cells. Activation of Src kinase by overexpressing kinase-dead Csk failed to reverse the inhibitory effect of Pyk2(Y402F), suggesting that osteoclastic bone resorption requires both c-Src kinase activity and the targeting of Src kinase by Pyk2. Src-catalyzed phosphorylation of Cbl on Tyr-731 is reported to induce the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function. Expressing the Cbl(Y731F) mutant in osteoclasts markedly reduced their bone resorbing activity, suggesting that phosphorylation of Cbl(Y731) and the subsequent recruitment and activation of phosphatidylinositol 3-kinase may be critical signaling events downstream of Src in osteoclasts.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14739300     DOI: 10.1074/jbc.M311032200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  101 in total

1.  Apatite-mediated actin dynamics in resorbing osteoclasts.

Authors:  Frédéric Saltel; Olivier Destaing; Frédéric Bard; Diane Eichert; Pierre Jurdic
Journal:  Mol Biol Cell       Date:  2004-09-15       Impact factor: 4.138

2.  Regulation of sealing ring formation by L-plastin and cortactin in osteoclasts.

Authors:  Tao Ma; Kavitha Sadashivaiah; Nandakumar Madayiputhiya; Meenakshi A Chellaiah
Journal:  J Biol Chem       Date:  2010-07-22       Impact factor: 5.157

3.  Mutation in Osteoactivin Promotes Receptor Activator of NFκB Ligand (RANKL)-mediated Osteoclast Differentiation and Survival but Inhibits Osteoclast Function.

Authors:  Samir M Abdelmagid; Gregory R Sondag; Fouad M Moussa; Joyce Y Belcher; Bing Yu; Hilary Stinnett; Kimberly Novak; Thomas Mbimba; Matthew Khol; Kurt D Hankenson; Christopher Malcuit; Fayez F Safadi
Journal:  J Biol Chem       Date:  2015-04-02       Impact factor: 5.157

4.  Dynamin forms a Src kinase-sensitive complex with Cbl and regulates podosomes and osteoclast activity.

Authors:  Angela Bruzzaniti; Lynn Neff; Archana Sanjay; William C Horne; Pietro De Camilli; Roland Baron
Journal:  Mol Biol Cell       Date:  2005-05-04       Impact factor: 4.138

5.  Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation.

Authors:  Fumitaka Koga; Wanping Xu; Tatiana S Karpova; James G McNally; Roland Baron; Len Neckers
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-14       Impact factor: 11.205

6.  Osteoclasts: what do they do and how do they do it?

Authors:  Steven L Teitelbaum
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

7.  Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.

Authors:  John C Araujo; Géralyn C Trudel; Fred Saad; Andrew J Armstrong; Evan Y Yu; Joaquim Bellmunt; George Wilding; John McCaffrey; Sergio V Serrano; Vsevolod B Matveev; Eleni Efstathiou; Stephane Oudard; Michael J Morris; Bruce Sizer; Peter J Goebell; Axel Heidenreich; Johann S de Bono; Stephen Begbie; Jun H Hong; Eduardo Richardet; Enrique Gallardo; Prashni Paliwal; Susan Durham; Shinta Cheng; Christopher J Logothetis
Journal:  Lancet Oncol       Date:  2013-11-08       Impact factor: 41.316

8.  The 1,2,3-triazole derivative KP-A021 suppresses osteoclast differentiation and function by inhibiting RANKL-mediated MEK-ERK signaling pathway.

Authors:  Hye Jung Ihn; Doohyun Lee; Taeho Lee; Hong-In Shin; Yong Chul Bae; Sang-Hyun Kim; Eui Kyun Park
Journal:  Exp Biol Med (Maywood)       Date:  2015-03-13

9.  Bovine dentine organic matrix down-regulates osteoclast activity.

Authors:  Wantida Sriarj; Kazuhiro Aoki; Keiichi Ohya; Yuzo Takagi; Hitoyata Shimokawa
Journal:  J Bone Miner Metab       Date:  2009-03-20       Impact factor: 2.626

10.  The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.

Authors:  Angela C Hirbe; Anke J Roelofs; Desiree H Floyd; Hongju Deng; Stephanie N Becker; Lisa G Lanigan; Anthony J Apicelli; Zhiqiang Xu; Julie L Prior; Mark C Eagleton; David Piwnica-Worms; Michael J Rogers; Katherine Weilbaecher
Journal:  Bone       Date:  2009-01-23       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.